Taltz FDA Approval History
Last updated by Judith Stewart, BPharm on Sep 7, 2020.
FDA Approved: Yes (First approved March 22, 2016)
Brand name: Taltz
Generic name: ixekizumab
Dosage form: Injection
Company: Eli Lilly and Company
Treatment for: Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis
Taltz (ixekizumab) is a humanized interleukin-17A antagonist indicated for the treatment of:
- patients aged 6 years or older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
- adults with active psoriatic arthritis.
- adults with active ankylosing spondylitis.
- adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation.
Development timeline for Taltz
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
